Can the presence of significant coagulopathy be useful to exclude symptomatic acute pulmonary embolism?

Anaesthesia and Intensive Care

Volumn 41, Issue 3, 2013, Pages 322-327

  Ho, K M ^a   Tan, J A ^a  

^a ROYAL PERTH HOSPITAL   (Australia)

Author keywords

Coagulation; Diagnosis; Pneumonia; Sensitivity and specificity; Venous thromboembolism

Indexed keywords

D DIMER; FIBRINOGEN;

ACUTE DISEASE; ADULT; AREA UNDER THE CURVE; ARTICLE; AUSTRALIA; BLOOD CLOTTING DISORDER; CLINICAL ASSESSMENT; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FIBRINOGEN BLOOD LEVEL; HUMAN; INCIDENCE; INTERNATIONAL NORMALIZED RATIO; LUNG ANGIOGRAPHY; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; PARTIAL THROMBOPLASTIN TIME; PNEUMONIA; PREDICTIVE VALUE; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SYMPTOM; THROMBOCYTE COUNT;

EID: 84878238135     PISSN: 0310057X     EISSN: 14480271     Source Type: Journal    
DOI: 10.1177/0310057x1304100308     Document Type: Article

References (15)

1. Ho KM, Burrell M, Rao S, Baker R. Incidence and risk factors for fatal pulmonary embolism after major trauma: a nested cohort study. Br J Anaesth 2010; 105:596-602.
2. Ho KM, Chavan S. Prevalence of thrombocytosis in critically ill patients and its association with symptomatic acute pulmonary embolism. Thromb Haemost 2013; 109:272-279.
3. Torbicki A, Perrier A, Konstantinides S, Agnelli G, Galiè N, Pruszczyk P et al. Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J 2008; 29:2276-2315.
4. Ho KM, Yip CB, Duff O. Reactive thrombocytosis and risk of subsequent venous thromboembolism: a cohort study. J Thromb Haemost 2012; 10:1768-1774.
5. Duff OC, Ho KM, Maybury SM. In vitro thrombotic tendency of reactive thrombocytosis in critically ill patients: a prospective case-control study. Anaesth Intensive Care 2012; 40:472-478.
6. Walsh TS, Stanworth SJ, Prescott RJ, Lee RJ, Watson DM, Wyncoll D. Prevalence, management, and outcomes of critically ill patients with prothrombin time prolongation in United Kingdom intensive care units. Crit Care Med 2010; 38:1939-1946.
7. Tufano A, Guida A, Di Minno MN, Prisco D, Cerbone AM, Di Minno G. Prevention of venous thromboembolism in medical patients with thrombocytopenia or with platelet dysfunction: a review of the literature. Semin Thromb Hemost 2011; 37:267-274.
8. Senzolo M, Sartori MT, Lisman T. Should we give thromboprophylaxis to patients with liver cirrhosis and coagulopathy? HPB (Oxford) 2009; 11:459-464.
9. Tripodi A, Chantarangkul V, Mannucci PM. Acquired coagulation disorders: revisited using global coagulation/anticoagulation testing. Br J Haematol 2009; 147:77-82.
10. Bagot CN, Arya R. Virchow and his triad: a question of attribution. Br J Haematol 2008; 143:180-190.
11. Ho KM, Chavan S, Pilcher D. Omission of early thromboprophylaxis and mortality in critically ill patients: a multicenter registry study. Chest 2011; 140:1436-1446.
12. Park MS, Martini WZ, Dubick MA, Salinas J, Butenas S, Kheirabadi BS et al. Thromboelastography as a better indicator of hypercoagulable state after injury than prothrombin time or activated partial thromboplastin time. J Trauma 2009; 67:266-275.
13. Boyce H, Hume-Smith H, Ng J, Columb MO, Stocks GM. Use of thromboelastography to guide thromboprophylaxis after caesarean section. Int J Obstet Anesth 2011; 20:213-218.
14. Attaran S, Somov P, Awad WI. Randomised high- and low-dose heparin prophylaxis in patients undergoing thoracotomy for benign and malignant disease: effect on thrombo-elastography. Eur J Cardiothorac Surg 2010; 37:1384-1390.
15. Ho KM. Ten commandments of interpreting and applying results of biomarker research. Anaesth Intensive Care 2011; 39:799-801.